Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opicapone add-on to levodopa/DDCI in early idiopathic Parkinson's disease
2020-005011-52Phase 3Completed
- Sponsor
- BIAL
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of opicapone in Parkinson's disease (PD) (3 arms), sponsored by BIAL. Primary endpoint: Change from baseline to end of double-blind period in MDS-UPDRS Part III total score. Started Mar 2021; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2020-005011-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005011-52.